Open-Label Clinical Trial Evaluating the Impact of a Multi-Strain Commensal Probiotic Dietary Supplement on Gastrointestinal Microbiota Composition, Functional Gastrointestinal Markers, and Gastrointestinal Symptoms

Inclusion criteria

• Adult females or males age ≥ 18 years
• At least moderate gastrointestinal distress, defined as a score of ≥ 4 on any domain of the Gastrointestinal Symptoms Rating Scale (GSRS) at screening
• Ability to read and speak English
• Ability and willingness to collect an at-home stool sample for GI-MAP testing

Exclusion criteria

• Current or recent (within the prior 90 days) use of a probiotic dietary supplement
• Current or recent (within the prior 90 days) use of systemic antibiotics, antifungals, or antiparasitic medications
• Known allergies to any ingredients in the product
• Currently pregnant or lactating women or women planning to become pregnant in the next 8 weeks
• Current diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis), celiac disease, active gastrointestinal malignancy, or other chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
• Severely immunocompromised status (e.g., active chemotherapy, post-transplant immunosuppression, advanced HIV)
• Participants unable to provide consent